Evidence map›Paper›PMID 34906633›Full record

SynthesisAnnals of epidemiology2022

Inflammatory markers in women with reported benign gynecologic pathology: an analysis of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Lauren A King, Nicolas Wentzensen, Mark P Purdue, Hormuzd A Katki, Ligia A Pinto, Britton Trabert

Open access · greenAbstract readMeta-Analysis
In one paragraph

Synthesis in Annals of epidemiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Lauren A KingDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD; University of Virginia School of Medicine, Department of Obstetrics and Gynecology, Charlottesville, VA. Electronic address: lak9um@virginia.edu.
Nicolas WentzensenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Mark P PurdueDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Hormuzd A KatkiDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Ligia A PintoFrederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD.
Britton TrabertDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
National Cancer Institute · USFrederick National Laboratory for Cancer Research · USVirginia Cancer Institute · US

Funding

PLCO Trial Etiologic and Early Marker StudyZIACP010152 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MOORE, STEVEN · 2009 to 2025
$29.9M
Therapeutic and Diagnostic Factors as Related to Cancer RiskZIACP010128 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$8.1M
Intramural NIH HHS ZIA CP010128
6 · The paper itself

Abstract

backgroundAssociations between benign gynecologic pathologies and circulating inflammatory markers are unknown. Our goal was to evaluate self-reported history of benign gynecologic pathology and subsequent alterations in systemic inflammation.

methodsUsing nested case-control studies from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, study-specific associations between self-reported history of benign ovarian cysts, uterine fibroids, and endometriosis with inflammatory marker concentrations were evaluated using logistic regression and combined using meta-analysis. Inflammatory markers associated with individual benign pathologies were mutually adjusted for one another to evaluate independent associations.

resultsCompared to women without a self-reported history of the pathology evaluated, benign ovarian cysts were associated with increased PAI-1 (OR [95% CI] 6.24 [2.53-15.39], P <.001) and TGF-β1 (3.79 [1.62-8.86], P =.002) and decreased BCA-1 (0.38 [0.19-0.73], P =.004). Uterine fibroids were associated with decreased CXCL11 (0.37 [0.22-0.63], P <.001) and VEGFR3 (0.40 [0.24-0.65], P <.001). Endometriosis was associated with increased SIL-4R (4.75 [1.84-12.26], P =.001).

conclusionsSelf-reported history of benign gynecologic pathologies were associated with alterations in inflammatory markers that have been previously linked to cancer risk. Understanding interactions between benign gynecologic pathologies and the systemic immune system may help inform disease risk later in life.

Indexed as

Colorectal NeoplasmsOvarian NeoplasmsClinical Trials as TopicEarly Detection of CancerFemaleHumansLogistic ModelsLungMaleProstateCancer riskEndometriosisInflammationLeiomyomaOvarian cysts

Identifiers

PMID34906633
PMCPMC8972075
OpenAlexW4200608731

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.